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ABSTRACT
Background: Results of leptin administration in mice, rats, and
humans provide a rationale for therapeutic augmentation of cir-
culating leptin (OB protein) concentrations in obese humans;
this may reduce food intake, increase metabolic rate, and lower
body mass.
Objective: We assessed the effects of weekly subcutaneous
pegylated polyethylene glycol (PEG)-OB protein administration
on appetite and energy metabolism in obese men.
Design: We performed a randomized, double-blind, placebo-
controlled trial in 30 obese men [body mass index (in kg/m2):
34.2 ± 3.6; age: 44.7 ± 7 y]. Subjects received 20 mg PEG-OB pro-
tein/wk for 12 wk while limiting their energy intake to 2.1 MJ/d.
Results: During treatment, appetite and hunger before breakfast
decreased and remained lower in the PEG-OB-protein group,
whereas they increased and remained higher in the placebo group
(P < 0.0001). During treatment, hunger decreased in the PEG-
OB-protein group (P < 0.05) and cognitive restraint increased in
the placebo group (P < 0.0001). Neither appetite nor food intake
changed significantly during the ad libitum evening meal. Under
energy balance conditions in the respiration chamber, appetite at
the end of treatment was not significantly different from baseline
despite similar, significant reductions in 24-h energy intake,
energy expenditure, sleeping metabolic rate, body mass, fat mass,
and fat-free mass (P < 0.01 for all) in both groups.
Conclusion: Treatment with PEG-OB protein modified subjec-
tive appetite at a dosage that produced no changes in body com-
position, energy expenditure, or body mass loss relative to
placebo treatment, suggesting that PEG-OB protein has central
rather than peripheral biological activity in obese men. Am J
Clin Nutr 2001;74:426–34.
KEY WORDS Obesity, leptin, OB protein, PEG-OB protein,
appetite, respiration chamber, universal eating monitor, energy balance,
hunger, satiety, food intake, underreporting, energy expenditure,
body mass, body composition, weight reduction, weight loss
INTRODUCTION
Obesity is a medical condition associated with relatively high
rates of morbidity and early mortality if it remains untreated
(1–4). Commonly used weight-control methods, such as diet and
exercise (5) and pharmacologic approaches (6), often produce
short-term success, but sustained weight maintenance after
weight reduction is generally difficult to achieve (5, 7). For this
reason and also because the prevalence of obesity is increasing
(8–10), other treatments that may be effective in the long term
should be considered.
Leptin, or OB protein, is a circulating hormone that was iden-
tified as a possible energy balance regulator. Leptin was discov-
ered after the positional cloning of the OB gene (11), which is
expressed in tissues such as adipose tissue and the placenta (12).
Serum leptin concentrations change in response to factors that
are known to affect body weight (12, 13). Moreover, genetic evi-
dence that leptin may be an important energy balance regulator
in humans was obtained in research on subjects with congenital
leptin deficiency; these individuals had severe obesity (14).
It was shown that blood leptin concentrations correlated with
percentage body fat and were elevated in obese individuals (15).
Despite the presence of elevated leptin concentrations, which
should reduce food intake and body fat, obese persons appear to
be insensitive or resistant to leptin and continue to maintain high
body fat. It was also reported that leptin concentrations
decreased with weight loss in obese individuals but leptin later
increased with weight regain (16).
In lean and obese mice and rats, intraperitoneal or subcuta-
neous leptin administration was associated with dose-dependent
reductions in food intake and body weight (17–19). Increased
energy expenditure during leptin treatment was observed in food-
restricted lean mice (20). The authors concluded that leptin con-
trols thermoregulatory energy expenditure when food supplies
are scarce but alters food intake, rather than energy expenditure,
when food is abundant (20). These observations suggest that
recombinant human leptin has potential in the treatment of human
obesity. Moreover, it was suggested that exogenously adminis-
tered leptin crosses the blood-brain barrier in humans, even
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though it is expected that the high serum leptin concentrations
would saturate the transport system (21). The existence of a trans-
port pathway that cannot be saturated was proposed, and more
than one pathway may be involved in the transport of leptin to the
brain (21). Thus, administration of exogenous leptin can be stud-
ied to determine whether increasing cerebrospinal fluid leptin
concentrations results in weight loss in obese persons (21).
The only human studies that are available to support these sug-
gestions are preliminary intervention trials. In trials sponsored by
Amgen Pharmaceuticals (Thousand Oaks, CA), significant dose-
related reductions in body fat and body weight were observed
after daily subcutaneous injections of 0.01–0.30 mg recombinant
human met-leptin/kg body weight for 24 wk in obese subjects
(22). In addition, treatment of a young, severely obese girl with
daily met-leptin caused dramatic reductions in appetite, food-
seeking behavior, food intake, and body weight (23).
Polyethylene glycols (PEGs) are amphophilic polymers of eth-
ylene glycol with various average molecular weights. PEGs can be
activated and covalently attached to proteins. Modification of pro-
teins with PEGs increased their serum half-lives and decreased
immunogenicity to several proteins (24). The average molecular
mass of the branched PEG that we used is 42 kD (25, 26).
In this study, we assessed the effects of weekly subcutaneous
injections of human recombinant PEG-OB protein on the
appetite profile and energy metabolism in obese men, under
conditions of mild energy-intake deficit. We tested the null
hypothesis that no differences in appetite, food intake, body
weight, body composition, or energy expenditure would be
observed. The term PEG-OB protein is used for the human
recombinant pegylated PEG-OB protein that was administered
and leptin for the endogenous substance.
SUBJECTS AND METHODS
Study design
The design was a prospective, randomized, double-blind,
placebo-controlled group study of 30 obese men. The study was
divided into 3 phases: 1) screening and baseline characterization,
2) PEG-OB protein or placebo treatment for 12 wk, and 3) fol-
low-up for 2 wk. Some of the results of this study were published
elsewhere (27).
Subject selection and screening
Subjects were recruited by means of advertisements in local
newspapers. Individuals who were willing to participate in the
study underwent a medical screening after they gave their writ-
ten, informed consent. This study was conducted according to
the Guidelines for Good Clinical Practice and the Declaration of
Helsinki (as amended in Tokyo, Venice, and Hong Kong) and
was monitored by Hoffmann-La Roche Inc (Welwyn, United
Kingdom). The screening included a full medical history and
physical examination; clinical laboratory tests (eg, hematologic,
biochemical, serologic, and urine analyses); a 12-lead electro-
cardiogram; and measurement of vital signs (supine and standing
blood pressure and heart rate, body temperature, and respiratory
rate). The screening visit was performed within the 6 wk before
the baseline period.
To be eligible for inclusion, subjects had to be male; be 18–60 y
old; have a body mass index (BMI; in kg/m2) ≥ 27.0; be healthy
on the basis of clinical laboratory assessments, physical exami-
nation, medical history, and vital signs; have no comorbid con-
ditions; be nonsmokers or smoke ≤ 5 cigarettes or the equiva-
lent/d; and be willing to give informed consent and comply with
the study procedures. The exclusion criteria were obesity of a
diagnosed endocrine origin; any significant physical or medical
illness, including laboratory or electrocardiogram abnormalities,
chronic infection, malignancy, or abnormal respiratory, cardio-
vascular, endocrine, gastrointestinal, renal, hepatic, hematologic,
pancreatic, pulmonary, or neurologic function; and weight loss
of > 3 kg in the 3 mo previous to screening. Subjects selected for
the study had to maintain their body weight from the time of
screening until the study began. Additional exclusion criteria
were current or past drug abuse or alcoholism, a history of psy-
chotic illness at any time, attempted suicide or parasuicide at any
time, current neurosis, use of any prescription medication within
2 wk or any over-the-counter medication within 72 h of the first
administration of the test drug, or anticipation of the need for such
medication during the course of the study. Potential subjects
were also excluded if they had a known allergy or hypersensitiv-
ity to PEG-OB protein, PEG, or pegylated proteins; a relevant
allergy to pharmaceutical agents; or a history of atopy.
PEG-OB protein
PEG-OB protein is a recombinant native human OB protein,
expressed and purified from Escherichia coli and chemically con-
jugated to a species of branched PEG molecule with an average
molecular weight of 42 kD in a 1-to-1 ratio. This resulted in a
globular PEG–native human OB-protein polymer with increased
molecular size (25, 26). PEG-OB protein at a concentration of
10 g/L was placed in sterile glass vials containing 1.3 mL; of the
1.3 mL available, 1.0 mL was taken out for use.
Procedures
Subjects were stratified and matched in pairs according to
age, BMI, and fasting serum leptin and insulin concentrations to
achieve balanced treatment with use of a frequency-based
approach. Randomization numbers for the subjects were gener-
ated and incorporated into the double-blind labeling by a third
party. The subjects then entered into the second part of phase 1,
baseline characterization.
Baseline characterization
Baseline characterization was performed for each subject dur-
ing the 2 wk before the 12-wk treatment phase. Baseline charac-
terization included assessment of the appetite profile, daily
energy intake, daily energy metabolism, 24-h energy metabo-
lism, sleeping metabolic rate (SMR), and substrate utilization.
We also measured body mass, body composition, and fasting
serum leptin concentrations.
Appetite profile
The appetite profile was assessed at 3 different times: when
subjects were fasting (before breakfast), in between meals dur-
ing the day, and at an ad libitum evening meal. The appetite pro-
file also included assessment of the degree of dietary restraint,
which was determined by completion of a validated Dutch trans-
lation (28, 29) of the Three Factor Eating Questionnaire (TFEQ;
30) on day 1.
The appetite profile before breakfast and in between meals
was determined from ratings of hunger, satiety, fullness, desire
to eat, estimate of prospective consumption, thirst, and appetite
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on 100-mm anchored visual-analogue scales (VAS) (29). The
appetite profile before breakfast was completed on the day when
subjects received the first injection (day 15 of the baseline char-
acterization, which was day 1 of the treatment phase). It was
completed 15 min before the first injection with PEG-OB protein
or placebo. Breakfast was provided after the injection.
The appetite profile in between meals was completed during
the 14-h daytime portion of a 36-h stay in the respiration cham-
ber, which was the last day before the treatment phase started
(day 14). The subjects were fed to maintain energy balance by
matching their energy intake with their calculated energy expen-
diture, on the basis of their observed SMR and a physical activ-
ity level of 1.7. Subjects were fed meals of specified composition
and size at fixed times during the day (29). Total energy intake
was distributed as follows: 15% from breakfast, 25% from lunch,
40% from dinner, and 20% from snacks.
The macronutrient composition of the meals and snacks was
as follows: 45% of energy from carbohydrate, 15% from protein,
and 40% from fat. The energy density of breakfast was 6.7 kJ/g,
of lunch was 8.4 kJ/g, of dinner was 4.4 kJ/g, and of snacks was
4.7 kJ/g. Calculations of energy density excluded water, coffee,
and tea, which were available ad libitum. The appetite profile
was completed at 10 fixed times in between meals: before and
after breakfast, midmorning, before and after lunch, midafter-
noon, before and after dinner, midevening, and before going to
sleep (29). Appetite during an ad libitum meal was assessed by
measuring hunger, satiety, the amount eaten, meal duration, and
the eating rate during a meal served from the Universal Eating
Monitor (28, 31–34) on the evening before subjects entered the
respiration chamber (day 13).
The Universal Eating Monitor consists of an electronic
scale built into a table under the plate that the subject eats
from; the scale is connected to a digital computer. Each time
the subject takes a bite, the new weight of the plate is
recorded by the computer. This technique provides a detailed
record of food intake during a meal. In addition to recording
the amount eaten, the meal duration, and the eating rate, it
records bite frequency and bite size. As a result, it provides a
cumulative food intake curve over time. The main course of
the meal was pasta with sauce (energy density, 5.1 kJ/g;
macronutrient composition: 44% of energy from carbohy-
drate, 16% from protein, and 40% from fat). The dessert was
chocolate mousse (energy density: 10.5 kJ/g; macronutrient
composition: 41.9% of energy from carbohydrate, 3.9% from
protein, and 54.1% from fat).
Daily energy intake and daily energy metabolism
Daily energy intake under free-living conditions was
assessed with food diaries that the subjects kept during the first
week of baseline characterization. We checked these data by
assessing energy expenditure with the doubly labeled water
technique, according to the Maastricht protocol (35, 36). On the
evening of day 0, subjects were given a weighed dose of a mix-
ture of 99.84 atom% 2H20 in 10.05 atom% H218O, such that
baseline concentrations were increased to > 300 ppm for 2H and
> 2300 ppm for 18O. A background urine sample was collected
on the evening of day 0. Additional urine samples were col-
lected on day 1 (the second void and again in the evening), in
the morning and evening of day 8, and in the morning and
evening of day 15 (35, 36). Samples were analyzed with isotope
ratio mass spectrometry (Aqua Sira; VG Isogas Ltd, Mid-
dlewich, United Kingdom). In this type of spectrometer, 18O is
measured in water vapor. Water vapor is produced from the sam-
ples by online vacuum distillation. Deuterium is measured in
hydrogen gas, which is produced from the samples online by the
hot uranium technique (36).
24-h Energy metabolism, sleeping metabolic rate, and substrate
utilization
SMR and 24-h energy metabolism were determined during
each subject’s stay in the respiration chamber. Measurements
were made from the evening of day 13 until the morning of day
15, in the baseline-characterization period.
The respiration chamber is a 14-m3 room furnished with a
bed, a chair, a computer, a television, a radio-cassette player,
a telephone, an intercom, a sink, and a toilet. The chamber is
ventilated with fresh air at a rate of 70–80 L/min. The venti-
lation rate was measured with a dry gas meter (type G4;
Schlumberger, Dordrecht, Netherlands). The concentrations
of oxygen and carbon dioxide were measured with paramag-
netic oxygen analyzers (Magnos 6G; Hartmann & Braun,
Frankfurt, Germany and type OA 184A; Servomex, Crowbor-
ough, United Kingdom) and infrared carbon dioxide analyzers
(type Uras 3G; Hartmann & Braun). During each 15-min
period, 6 samples of outgoing air from each of the 2 chambers
and 1 sample each of fresh air and calibration gas were meas-
ured. The gas samples to be measured were selected by a
computer that also stored and processed the data (37). Sub-
jects also had to follow a standardized physical activity pro-
gram including controlled exercise on a bicycle ergometer
(Lode, Groningen, Netherlands) at 45% of the predicted max-
imal capacity. Subjects cycled for 45 min during the morning
(from 1000 to 1045). In the afternoon, 30 min of cycling was
scheduled (from 1500 to 1530).
SMR was calculated from 0300 to 0600, with values controlled
for physical activity by a Doppler radar system (37). Substrate uti-
lization was calculated from oxygen consumption and carbon
dioxide production over 24 h, corrected for protein utilization as
indicated by nitrogen excretion in the collected 24-h urine sample.
Body mass and body composition
Body mass was measured with a digital scale accurate to 0.01 kg
(model E1200; Sauter Inc, Ebingen, Germany) and height was
measured to the nearest 0.001 m with use of wall-mounted cali-
brated meter scales. BMI was calculated from body weight and
height (in kg/m2). Body composition was determined by using
hydrodensitometry and isotope dilution (36) with the combined
equation of Siri (38; Table 1).
Serum leptin concentrations
Fasting blood samples for the measurement of serum leptin and
PEG-OB protein concentrations were collected weekly before the
next dose of PEG-OB protein or placebo. The samples were ana-
lyzed by Hoffmann-La Roche, Nutley, NJ. For the baseline char-
acterization, the fasting blood sample was obtained on day 15 after
the subjects left the respiration chamber. Serum leptin concentra-
tions were measured with a double-antibody, sandwich-type
enzyme-linked immunosorbent assay that used a monoclonal anti-
body specific for human leptin. The lower limit of detection is
0.5 g/L and the upper limit is 50 g/L. The intra- and interassay
CVs were 9% and 12%, respectively. The leptin concentrations of
normal-weight subjects range from 2 to 12 g/L. To measure the
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pharmacokinetics of leptin and PEG-OB protein, a frequent sam-
pling schedule was applied in weeks 1 and 12 (27).
Treatment phase
Subjects received 20 mg PEG-OB protein (2 mL, 10 g/L) or
placebo (2 mL of the buffer solution used for the PEG-OB pro-
tein) subcutaneously in the paraumbilical region once per wk for
12 wk while in a fasting state. Treatment started immediately
after the screening and baseline characterization phase was com-
pleted (ie, after the subject left the respiration chamber). All sub-
jects in both groups were prescribed a diet calculated to cause an
energy deficit of 2.1 MJ/d throughout the study. Subjects dis-
cussed their diets every 2 wk with a dietitian. Vital signs and
body mass were measured and standard laboratory tests were
performed. The measurements made for baseline characteriza-
tion were repeated in all subjects at the end of the treatment
period by using the procedures described above.
In addition, subjects completed the appetite profile weekly
before breakfast. Appetite between meals (over 14 h) was meas-
ured during a 36-h stay in the respiration chamber from day 83
to day 85 of the treatment period. During this same time period,
SMR, 24-h energy metabolism, and substrate oxidation were
also determined. Appetite and food intake during the ad libitum
evening meal were assessed before entering the respiration
chamber on day 83. Also, the TFEQ was completed on day 83
of the treatment period. During week 11, food intake was
assessed again by using a food diary; the results were checked
by using the doubly labeled water method. After 12 wk of treat-
ment (on day 85), body mass and body composition were deter-
mined. The changes in subject characteristics from day 1 to day
85 are shown in Table 1.
Follow-up
The follow-up was conducted over the 2-wk period after the
last dose of placebo or PEG-OB protein. We assessed the sub-
jects’ vital signs and body mass.
Safety
The safety of PEG-OB protein was monitored during each
visit by documenting any adverse events and recording vital
signs on case report forms. Routine clinical hematology and bio-
chemical tests and urinanalyses were done weekly (27). The
safety data were reviewed first for both groups combined and
then for each group separately.
Data analysis
Changes from baseline to 12 wk were compared between the
PEG-OB protein and placebo groups with a two-factor repeated-
measures analysis of variance (ANOVA) with a group  time
interaction. A post hoc Scheffe’s procedure was used. To deter-
mine how representative the appetite profile ratings before
breakfast were, these were compared with the average profile
ratings from 10 time points over 14 h during the same day by
using repeated-measures ANOVA. All statistics were executed
with STATVIEW+GRAPHICS (Abacus Concepts Inc, Berkeley,
CA). Significance was defined as P < 0.05.
RESULTS
During the 12-wk treatment period, sustained serum concen-
trations of PEG-OB protein measured just before the next dose
ranged from 200 to 300 g/L. Mean peak serum PEG-OB pro-
tein concentrations were reached 72 h after the dose was given;
concentrations returned to the elevated predose concentrations
after 1 wk (27). Baseline total leptin concentrations did not dif-
fer between the PEG-OB protein and placebo groups. Serum lep-
tin concentrations increased to a new steady state amount in the
PEG-OB protein group, whereas total leptin concentrations
decreased with weight loss in the placebo group (Table 1).
Serum leptin concentrations differed significantly between the
groups from weeks 9 to 12 of the study (Figure 1; P < 0.05).
The weekly appetite profile ratings before breakfast showed a
change from baseline; appetite and hunger decreased in the PEG-
OB protein group but increased in the placebo group from days
1 to 8 (Figure 1). From days 8 to 78, these ratings were continu-
ously significantly lower in the PEG-OB protein group than in
the placebo group. The average values for desire to eat, estimate
of prospective consumption, satiety, and fullness over the 12-wk
period also differed significantly between the 2 groups (Table 2).
Thirst scores remained stable during the 12-wk intervention
period (Table 2). The differences between the groups in changes
in appetite ratings coincided with the significant difference in
change of serum leptin concentrations during weeks 9–11 (Fig-
ure 1). These ratings were assessed and blood samples were col-
lected on the same day each week, before breakfast.
Appetite profile ratings recorded for 14 h during the day in the
respiration chamber were not significantly different from baseline
at the end of the 12-wk treatment; they also did not differ signifi-
cantly between groups (Table 3). Appetite before breakfast in the
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TABLE 1
Subject characteristics in the 2 matched groups at baseline (day 1) and after 12 wk of treatment (day 85) with 20 mg pegylated polyethylene glycol OB
protein (PEG-OB protein) or placebo1
P
PEG-OB protein group (n = 15) Placebo group (n = 15) Group  time
Baseline After treatment Baseline After treatment interaction2 Time effect3
Body mass (kg) 107.3 ± 3.4 103.0 ± 3.0 108.6 ± 4.6 102.2 ± 4.1 NS 0.001
Fat mass (kg) 37.8 ± 3.3 33.9 ± 2.9 39.9 ± 4.4 33.9 ± 4.0 NS 0.01
Fat-free mass (kg) 69.5 ± 3.4 69.1 ± 3.0 68.7 ± 4.6 68.3 ± 4.1 NS NS
Age (y) 45 ± 2 44 ± 2
Leptin (g/L) 21.9 ± 4.9 24.0 ± 4.0 20.4 ± 4.9 14.6 ± 4.1 0.05 0.05
Insulin (mmol/L) 19.6 ± 10.3 18.5 ± 7.8 20.0 ± 6.2 16.7 ± 4.2 NS NS
1 x– ± SEM. There were no significant differences between the groups on day 1.
2 Two-factor repeated-measures ANOVA.
3 Repeated-measures ANOVA.
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TABLE 2
Appetite profile ratings on the visual analogue scale before breakfast at baseline (day 1) and during 12 wk of treatment (average of weekly values);
subjects were treated with 20 mg pegylated polyethylene glycol OB protein (PEG-OB protein) or placebo1
P
PEG-OB protein group (n = 15) Placebo group (n = 15) Group  time Within-group
Baseline During treatment Baseline During treatment interaction2 time effect3
mm mm
Appetite 54 ± 1.1 44.4 ± 1.13 55 ± 0.7 56.7 ± 0.8 0.0001 0.05
Hunger 50 ± 1.1 40.9 ± 1.13 50 ± 1.2 53.2 ± 1.2 0.0001 0.05
Estimate of prospective consumption 54 ± 0.8 47.3 ± 0.8 57 ± 0.6 56.7 ± 0.6 0.0001 NS
Desire to eat 53 ± 1.0 45.9 ± 1.0 58 ± 1.0 56.4 ± 1.0 0.001 NS
Thirst 60 ± 1.1 60.2 ± 1.1 60 ± 0.7 61.0 ± 0.7 NS NS
Satiety 35 ± 1.5 45.9 ± 1.53 35 ± 0.7 36.8 ± 0.7 0.0001 0.05
Fullness 36 ± 1.2 44.0 ± 1.23 32 ± 0.9 36.5 ± 0.9 0.0001 0.05
1 x– ± SEM.
2 Two-factor repeated-measures ANOVA.
3 Repeated-measures ANOVA with Scheffe’s procedure.
FIGURE 1. Visual analogue scale (VAS) ratings of appetite and hunger and serum leptin values in the subjects who received 20 mg pegylated poly-
ethylene glycol OB protein (PEG-OB protein; n = 15) or placebo (n = 15). All data were collected before breakfast. There were significant differences
in changes in appetite and hunger during treatment between the 2 groups (two-factor repeated-measures ANOVA with interaction; P < 0.01). There
were significant differences in changes in serum leptin concentrations during treatment between the 2 groups (two-factor repeated-measures ANOVA
with interaction; P < 0.05).
respiration chamber was not significantly different from appetite
before breakfast measured separately during the same week
(Tables 2 and 3) and differed significantly between the groups
after treatment. However, the average appetite before breakfast
in the respiration chamber differed from the average appetite
throughout the same day (Table 3; P < 0.0001), thus, the appetite
profile before breakfast was not representative of the appetite
profile during the day.
Appetite and food intake did not differ significantly between
the groups during the ad libitum meal at baseline or after the
12-wk intervention. There was no significant change in these
appetite indexes from baseline to the end of treatment (Table 4).
With respect to the general attitude toward eating, scores on
cognitive restraint (factor 1) in the placebo group increased
significantly (F1,14 = 26.4; P < 0.0001) and scores on hunger
(factor 3) in the PEG-OB protein group decreased significantly
(F1,14 = 5.6; P = 0.03) from baseline to the end of the 12-wk treat-
ment (Table 5). The other scores on the TFEQ did not change
significantly from baseline to the end of treatment (F1,14 ≤ 4.3;
NS). The changes in TFEQ scores over the 12-wk treatment were
significantly different between the groups with respect to cogni-
tive restraint (F1,28 = 4.94; P = 0.03); the other differences
between groups in the changes [disinhibition (factor 2) and
hunger] were not significant (F1,28 ≤ 0.85; NS; Table 5).
Daily energy intake, calculated from self-reported food intake
recorded in the food diaries, decreased by 2.6 MJ from baseline
to the end of treatment in the PEG-OB protein group (P < 0.001)
and by 2.2 MJ in the placebo group (P < 0.001). Self-reported
energy intake did differ significantly between the groups. The
diaries indicated that these decreases in energy intake resulted
from reductions in meal size during breakfast and dinner and
reductions in meal frequency from 5.3 to 4.4 eating episodes/d
(P < 0.03). In both groups, the reported macronutrient composi-
tion shifted from 39% of energy from carbohydrate, 16% from
protein, 39% from fat, and 6% from alcohol to 40%, 20%, 35%,
and 5% of energy, respectively. The reported percentage of
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TABLE 4
Food intake during the ad libitum meal from the Universal Eating Monitor (28) at baseline and after 12 wk of treatment1
PEG-OB protein group (n = 15) Placebo group (n = 15)
Baseline After treatment Baseline After treatment
Amount eaten (MJ)
Main course 2.3 ± 0.3 2.1 ± 0.2 2.0 ± 0.3 2.1 ± 0.3
Dessert 1.3 ± 0.2 1.3 ± 0.2 1.1 ± 0.2 1.2 ± 0.2
Eating rate (g/min)
Main course 70 ± 8 63 ± 6 57 ± 6 63 ± 5
Dessert 62 ± 9 68 ± 7 57 ± 7 62 ± 9
Meal duration (min)
Main course 6.5 ± 0.8 6.6 ± 0.8 6.8 ± 0.9 6.5 ± 0.7
Dessert 2.0 ± 0.3 1.8 ± 0.2 1.9 ± 0.2 1.8 ± 0.2
Change in hunger on VAS (mm/min)
Main course 5.9 ± 1.2 5.9 ± 1.2 2.1 ± 4.1 2.1 ± 4.1
Dessert 2.9 ± 0.8 2.9 ± 0.8 4.1 ± 1.3 4.1 ± 1.3
Change in satiety on VAS (mm/min)
Main course 6.6 ± 1.3 6.2 ± 1.6 7.8 ± 1 8.4 ± 1.9
Dessert 3.7 ± 3.1 3.7 ± 3.1 5.1 ± 1.6 5.1 ± 1.6
1 x– ± SD. There were no significant group  time interactions, time effects, or group differences. VAS, visual analogue scale.
TABLE 3
Appetite profile ratings on the visual analogue scale at baseline (day 1) and after 12 wk of treatment (day 85) with 20 mg pegylated polyethylene glycol
OB protein (PEG-OB protein) or placebo1
PEG-OB protein group (n = 15) Placebo group (n = 15) P2
Baseline After treatment Baseline After treatment Group  time Within-group
14 h BB3 14 h BB3 14 h BB3 14 h BB3 interaction4 time effect5
mm mm
Appetite 30 ± 2 54 ± 2 33 ± 5 44 ± 14,5 37 ± 4 55 ± 2 33 ± 3 57 ± 24 0.001 0.05
Hunger 27 ± 3 50 ± 1 30 ± 4 41 ± 14,5 31 ± 5 50 ± 2 31 ± 3 53 ± 24 0.001 0.05
Estimate of prospective 36 ± 4 54 ± 2 36 ± 4 47 ± 14 37 ± 4 57 ± 2 37 ± 4 57 ± 14 0.001 NS 
consumption
Desire to eat 31 ± 4 53 ± 1 34 ± 5 46 ± 14 33 ± 3 58 ± 2 35 ± 4 58 ± 24 0.001 NS
Thirst 44 ± 4 60 ± 1 44 ± 5 61 ± 2 54 ± 5 60 ± 2 35 ± 3 61 ± 2 NS NS
Satiety 62 ± 5 35 ± 1 66 ± 5 46 ± 14,5 63 ± 5 35 ± 1 66 ± 6 36 ± 14 0.001 0.05
Fullness 62 ± 5 36 ± 1 64 ± 5 44 ± 24,5 64 ± 6 32 ± 1 65 ± 5 35 ± 24 0.001 0.05
1 x– ± SEM. Measurements were made over 14 h and before breakfast (BB) during the day in the respiration chamber (8–22 h).
2 For BB values only.
3 All values significantly different from 14-h values, P < 0.01 (repeated-measures ANOVA).
4 Two-factor repeated-measures ANOVA.
5 Repeated-measures ANOVA with Scheffe’s procedure.
energy from protein increased (P < 0.05). However, when con-
trolled for energy expenditure as measured by the doubly labeled
water technique, reported energy intake showed an underreport-
ing of 37% at baseline and of 48% after 12 wk of treatment (35).
Daily energy expenditures in the PEG-OB protein and placebo
groups, respectively, were 16.5 ± 2 and 17.0 ± 2.8 MJ/d at base-
line and 15.4 ± 2 and 14.7 ± 2.2 MJ/d at the end of the 12-wk treat-
ment. This reflects energy expenditure reductions of 1.1 ± 1 MJ/d
in the PEG-OB protein group and of 2.3 MJ/d in the placebo
group; the difference between the groups was not significant.
In the respiration chamber, energy balance was achieved at a
level of 0.02 to 0.20 MJ, which did not differ significantly
from 0. After 12 wk of treatment with PEG-OB protein or
placebo, there were no significant differences in energy expendi-
ture, SMR, or substrate oxidation between the groups (Table 6).
Energy expenditure was, on average, 93% of the energy expen-
diture at baseline. In both groups, 24-h energy expenditure and
SMR during energy balance were significantly reduced after
12 wk. SMR expressed as a function of fat-free mass did not
change significantly from baseline to the end of the 12-wk treat-
ment, nor did it differ significantly between the groups after
treatment. The respiratory quotient did not change significantly
over the 12-wk treatment phase. The physical activity index in
the respiration chamber (determined by using the standardized
activity protocol) and the food quotient (determined by using the
standardized macronutrient composition of the food provided to
the subjects) did not change from baseline to the end of treat-
ment. Because subjects were fed to maintain energy balance dur-
ing their stays in the chamber, energy intake was significantly
reduced after 12 wk of treatment in each group, corresponding to
the significant reduction in energy expenditure.
There were no clinically relevant changes in mean laboratory
values or vital signs during the study. No differences in standard
chemistry or hematologic assessments were detected between the
groups. Mean total serum protein decreased significantly (2.3%)
in the PEG-OB protein group but not in the placebo group
(0.5%). However, no significant differences in urinary protein
were observed between the groups. In summary, at the dosage
studied, PEG-OB protein appeared to be generally well tolerated
and safe (27). At follow-up (2 wk after the last dose), vital signs
were normal and body mass had not changed significantly from
the last measurement made during the treatment phase.
DISCUSSION
Treatment of obese men with a weekly subcutaneous injection
of 20 mg PEG-OB protein, under conditions of an energy deficit
of 1–2 MJ/d, resulted in lower appetite and hunger ratings before
breakfast than in the placebo group. This difference began during
the first week after treatment started and it remained constant dur-
ing the next 11 wk. The changes in the appetite profile before
breakfast occurred while serum leptin concentrations changed in
different directions in the 2 groups: serum leptin increased and
remained higher in the PEG-OB protein group, whereas it
decreased, as expected, and remained lower in the placebo group.
As was shown before (12, 22, 23), increases in serum leptin con-
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TABLE 6
Energy metabolism at baseline (day 1) and after 12 wk of treatment (day 85) with 20 mg pegylated polyethylene glycol OB protein (PEG-OB protein) or
placebo1
PEG-OB protein group (n = 15) Placebo group (n = 15) P for time effect
Baseline After treatment Baseline After treatment (both groups)2
24-h EI (MJ/d) 14.1 ± 0.33 13.1 ± 0.3 13.8 ± 0.4 12.6 ± 0.3 0.0001
24-h EE (MJ/d) 14.1 ± 0.3 13.4 ± 0.3 14.0 ± 0.4 12.8 ± 0.4 0.001
FQ4 0.8 0.8 0.8 0.8
RQ5 0.84 ± 0.0003 0.84 ± 0.01 0.84 ± 0.0003 0.85 ± 0.01 NS
SMR (MJ/d) 8.5 ± 0.2 8.0 ± 0.2 8.3 ± 0.2 7.7 ± 0.2 0.001
PAL 1.7 ± 0.03 1.7 ± 0.03 1.7 ± 0.03 1.7 ± 0.02 NS
1 There were no significant group  time interactions and no significant differences between groups. EI, energy intake; EE, energy expenditure; FQ, food
quotient; RQ, respiratory quotient; SMR, sleeping metabolic rate; PAL, physical activity level (EE/SMR).
2 Repeated-measures ANOVA.
3 x– ± SEM.
4 FQ = carbon dioxide consumption ( ·VCO2)/oxygen consumption ( ·VO2) when the food is completely oxidized (30, 38).
5 RQ = ·VCO2/ ·VO2.
TABLE 5
Scores on the Three-Factor Eating Questionnaire at baseline (day 1) and after 12 wk of treatment with 20 mg pegylated polyethylene glycol OB protein
(PEG-OB protein) or placebo1
P
PEG-OB protein group (n = 15) Placebo group (n = 15) Group  time Within-group
Baseline After treatment Baseline After treatment interaction2 time effect3
Cognitive restraint 7.1 ± 1.4 9.3 ± 1.5 4.1 ± 0.6 9.5 ± 1.33 0.05 0.0001
Disinhibition 4.8 ± 0.6 4.8 ± 0.6 4.9 ± 0.6 4.7 ± 0.6 NS NS
Hunger 5.9 ± 1.2 4.3 ± 1.13 3.8 ± 0.7 3.0 ± 0.73 NS 0.05
1 x– ± SEM.
2 Two-factor repeated-measures ANOVA.
3 Repeated-measures ANOVA with Scheffe’s procedure.
centrations are related to decreased hunger, which occurred in the
PEG-OB protein group. Decreases in serum leptin are related to
increased hunger (12), which occurred in the placebo group.
Furthermore, it is important to remember that the appetite profile
VAS ratings were obtained in a fasted state, over 12 wk, while the
subjects were in negative energy balance. The finding of a relatively
reduced appetite under negative energy balance conditions is con-
sistent with the reduced food intake in rats after PEG-OB protein
treatment (17, 18) and with observations of appetite reduction by
Farooqi et al (23). During the 12 wk of treatment, the subjects in
both groups were in negative energy balance and appeared to be in
compliance with the dietary instructions that created this deficit.
Compliance with dietary instructions independent of treatment was
indicated by the increases in cognitive restraint scores of the TFEQ
(30, 39); these increases occurred in both groups but were signifi-
cant only in the placebo group because of the relatively lower level
of cognitive restraint (NS) at baseline in this group. At 12 wk, both
groups had an average level of cognitive restraint of 9, which is
the cutoff in our subject population for dietary restraint, as opposed
to unrestraint (28, 32, 33). Compliance was also indicated by the
average loss in body mass of 5.4 kg over 12 wk, which is consistent
with a reduction in energy intake of 1–2 MJ/d and a loss of 1 kg
body mass for every 30-MJ reduction in energy intake (5).
Another indicator of an effect of PEG-OB protein on the
appetite profile was the significant decrease in the general feel-
ing of hunger, as indicated by factor 3 (hunger) of the TFEQ.
This change was consistent with the finding of reduced appetite
and hunger as scored weekly in the fasting state. The hunger
scores on the TFEQ and the appetite profile scores before break-
fast appeared to be sensitive to the combination of PEG-OB pro-
tein treatment and negative energy balance in a fasted state. Also,
self-reported daily energy intake was significantly reduced in the
PEG-OB protein group at the end of treatment.
However, the relatively lower appetite before breakfast that we
observed in the PEG-OB-protein group was not associated with
reduced food intake during the ad libitum evening meal. Weekly
administration of 20 mg PEG-OB protein may have failed to reduce
observed food intake because the observed reduced appetite profile
before breakfast was measured during negative energy balance con-
ditions in the fasted state. It appeared that this finding was not rep-
resentative of appetite during the rest of the day; therefore, the
appetite profile data collected before breakfast was less meaningful.
This also means that the results of the present study regarding food
intake and body mass reduction did not agree with those of compa-
rable animal studies (17, 18, 20) and initial intervention studies in
humans (22, 23). The similar reductions in body mass that occurred
in both groups probably resulted from compliance with the diet.
Until now, only one study reported losses in body mass and fat mass
that were significantly different in leptin-treated subjects than in
placebo-treated subjects (22). In that study there was wide variabil-
ity in the response of subjects to daily subcutaneous administration
of 0.03 g recombinant methionyl human leptin/kg body wt (Amgen
Pharmaceuticals), resulting in a dose of 30 mg/d.
There were no significant changes from baseline to the end of
treatment in 24-h appetite profiles during energy balance. On the
basis of the energy-balance measurements in the respiration
chamber, energy expenditure decreased, on average, to 93% of
the original average daily metabolic rate. Apparently, a decrease
in energy expenditure was related to a lower body mass; together
these factors did not result in any change in the 24-h appetite
profile under energy-balance conditions. Moreover, the respira-
tory quotient did not change significantly from baseline to the
end of treatment, nor did it differ significantly between the 2 treat-
ment groups. The possible relations between substrate oxidation
and both hunger and satiety, as reported previously (29), might
explain, in part, why the appetite profiles did not change from
baseline to the end of treatment.
The similar reduction in energy expenditure in both groups
after 12 wk of treatment, under energy-balance conditions in the
respiration chamber, must have resulted mainly from the similar
losses of body mass, fat mass, and fat-free mass. In comparison,
there was a diminished decrease of metabolic rate in OB pro-
tein–treated mice under conditions of negative energy balance
(20). In the present study, subjects complied with dietary instruc-
tions designed to produce a negative energy balance, but the
treatment did not affect this negative energy balance as in the
OB protein–treated mice.
We conclude that a weekly subcutaneous injection of 20 mg
PEG-OB protein in obese men results in lower appetite and
hunger levels before breakfast than does placebo treatment.
These lower appetite and hunger levels occurred in the fasted
state during a period of negative energy balance. In contrast,
appetite and hunger levels increased from baseline to the end of
treatment in the placebo group. These effects occurred in paral-
lel to increased serum leptin concentrations in the PEG-OB pro-
tein group and to decreased serum leptin in the placebo group.
Moreover, a general reduction in hunger, as indicated by the
TFEQ, in the PEG-OB protein group during a period of negative
energy balance was observed compared with placebo treatment.
Reduced hunger in the PEG-OB protein group did not result in
reductions in daily food intake or body mass or changes in body
composition. The treatment also did not have an independent
effect on energy expenditure, ie, on the change in SMR as a func-
tion of fat-free mass.
When subjects were in short-term energy balance (at 93% of
the original energy expenditure), the lack of change in the
appetite profile from baseline to the end of treatment and the
absence of differences between treatments implies that the rela-
tively reduced hunger found in the fasted state before breakfast
was not representative of the 14-h appetite profile measured in
the respiration chamber.
The fact that PEG-OB protein treatment modified appetite at
a dosage that did not result in significant changes in body com-
position, energy expenditure, or body mass loss compared with
placebo treatment suggests that PEG-OB protein has central
rather than peripheral biological activity in obese men.
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